Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.08 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | reachable by antibody | 0.36 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 17 Parkinson's papers of 388 | 0.62 |
| pathways Reactome | 2 pathways; mostly mitochondrial quality control | 1.00 |
No case: the score is under the bar. Receipt 3317
Sealed predictions
- PGAM5 in dopamine neurons, braak+0.16 (p 0.680) → -0.88 (p 0.002)receipt 3324
Swarm cases
receipt 3324: PGAM5 in dopamine neurons, braak
- power
- full sample -0.22 (p 0.374, n 18), 95% CI -0.62 to +0.27. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.22 (p 0.374, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.22 (p 0.384, n 18). could be the mix.
- skeptic
- leave-one-out range -0.33 to -0.11, sign flips 0; without severely affected donors -0.22 (p 0.374, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for PGAM5 in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts